Precigen (PGEN)
(Delayed Data from NSDQ)
$0.96 USD
-0.03 (-3.10%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $0.96 0.00 (-0.44%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Precigen, Inc. [PGEN]
Reports for Purchase
Showing records 1 - 20 ( 25 total )
Company: Precigen, Inc.
Industry: Medical Services
PRGN-2012 Commercialization Takes Priority; Adjusting PT Down to $4; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Positive Pivotal Data With PRGN-2012 Paves Way for Regulatory Filing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Eyes on Pivotal Clinical Data of PRGN-2012 at ASCO; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
PRGN-2012 Launch on the Horizon; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Focus on PRGN-2012; Pipeline Progress Continues; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
FDA Agrees a Favorable Regulatory Pathway for PRGN-2012; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Eyes on PRGN-2012 Regulatory Pathway and PRGN-2009 ASCO Update; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Balance Sheet Strengthened; PRGN-2009 Updates Throughout 2023; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
PRGN-2012 Update on R&D Day; PRGN-3006 Data at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
UltraCAR-T Platform Achieved Manufacturing Milestone; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Trans Ova Divesture Removes Financial Overhang; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Steady Progress in Clinical Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Clinical Pipeline Development on Target; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Positive PRGN-3006 Update at ASH; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Solid Progress Across Pipeline, our Take from R&D Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Company: Precigen, Inc.
Industry: Medical Services
All Eyes on the Upcoming R&D Day; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Multiple Clinical Readouts Expected in 2H21; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
Encouraging Clinical Updates on UltraCAR-T Programs; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Precigen, Inc.
Industry: Medical Services
UltraCAR-T Platform?s Potential Validated; Higher PT to $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S